Atom Investors’s CASI Pharmaceuticals CASI Stock Holding History

Atom Investors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,389	Closed	-$27K	–	218
2021 Q4	$27K	Buy	+3,389	New	+$33.7K	﹤0.01%	258

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atom Investors's CASI Position: Q1 2022 in Review

Atom Investors sold out of CASI Pharmaceuticals (CASI) in Q1 2022, closing a stake of 3,389 shares — an estimated $27K sold.

Atom Investors first reported a position in CASI in Q4 2021 and held it in 1 quarter. The position peaked at $27K in Q4 2021. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2022.

Atom Investors reported no remaining CASI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Atom Investors sold 3,389 CASI Pharmaceuticals shares in Q1 2022, an estimated $27K.
Atom Investors first reported a position in CASI Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Atom Investors's CASI Pharmaceuticals position peaked at $27K in Q4 2021.
44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2022.

Based on Atom Investors's 13F filing for Q1 2022, filed 16 May 2022.